Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review.

ABSTRACT:

Background and objective

Immune checkpoint inhibitor (ICI)-based therapy has achieved impressive success in various cancer types. Several ICIs have been unprecedentedly approved as the treatment regimens for advanced hepatocellular carcinoma (HCC) in recent decade. Meanwhile, numerous clinical trials are being performed to exploit more ICIs into initially unresectable HCC and postoperative HCC to expectantly induce adequate tumor downstaging for further resection or implement adjuvant treatment for relapse-free survival, respectively. In this review, we aim to summarize some pragmatic histomorphologic, immunohistochemical, and molecular pathologic parameters which promisingly indicate the response of neoadjuvant/conversion ICI-related therapy and predict the efficacy of adjuvant/th

SUBMITTER: Wang H 

PROVIDER: S-EPMC11190517 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature